204 related articles for article (PubMed ID: 24096969)
21. Lipid lowering efficacy of atorvastatin.
Adams SP; Tsang M; Wright JM
Cochrane Database Syst Rev; 2012 Dec; 12():CD008226. PubMed ID: 23235655
[TBL] [Abstract][Full Text] [Related]
22. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
23. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
24. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
Geleedst-De Vooght M; Maitland-van der Zee AH; Schalekamp T; Mantel-Teeuwisse A; Jansen P
Drugs Aging; 2010 Jul; 27(7):589-96. PubMed ID: 20583852
[TBL] [Abstract][Full Text] [Related]
25. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
de Keyser CE; Peters BJ; Becker ML; Visser LE; Uitterlinden AG; Klungel OH; Verstuyft C; Hofman A; Maitland-van der Zee AH; Stricker BH
Pharmacogenet Genomics; 2014 Jan; 24(1):43-51. PubMed ID: 24263182
[TBL] [Abstract][Full Text] [Related]
26. Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis.
Geiss HC; Parhofer KG; Schwandt P
J Intern Med; 1999 Jan; 245(1):47-55. PubMed ID: 10095816
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ
Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893
[TBL] [Abstract][Full Text] [Related]
28. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
29. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.
Meyer BJ; Hammervold T; Rustan AC; Howe PR
Lipids; 2007 Mar; 42(2):109-15. PubMed ID: 17393216
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
Simpson RJ; Signorovitch J; Birnbaum H; Ivanova J; Connolly C; Kidolezi Y; Kuznik A
Mayo Clin Proc; 2009 Dec; 84(12):1065-72. PubMed ID: 19955243
[TBL] [Abstract][Full Text] [Related]
31. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
32. Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol.
Aronow HD; Hess G; Hill J; Kuznik A; Liu LZ
Am J Ther; 2010; 17(2):167-75. PubMed ID: 19770794
[TBL] [Abstract][Full Text] [Related]
33. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
Zhao SP; Yu BL; Peng DQ; Huo Y
Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
[TBL] [Abstract][Full Text] [Related]
34. Intensive statin therapy in acute coronary syndromes.
Liew TV; Ray KK
Curr Atheroscler Rep; 2008 Apr; 10(2):158-63. PubMed ID: 18417071
[TBL] [Abstract][Full Text] [Related]
35. Effect of 12-month statin therapy on antioxidant potential of LDL and serum antioxidant vitamin concentrations.
Vasankari T; Ahotupa M; Viikari J; Nuotio I; Strandberg T; Vanhanen H; Gylling H; Miettinen T; Tikkanen MJ
Ann Med; 2004; 36(8):618-22. PubMed ID: 15768833
[TBL] [Abstract][Full Text] [Related]
36. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Montouchet C; Ruff L; Balu S
J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
38. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
Stoekenbroek RM; Boekholdt SM; Fayyad R; Laskey R; Tikkanen MJ; Pedersen TR; Hovingh GK;
Heart; 2015 Mar; 101(5):356-62. PubMed ID: 25595417
[TBL] [Abstract][Full Text] [Related]
39. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
Insull W; Ghali JK; Hassman DR; Y As JW; Gandhi SK; Miller E;
Mayo Clin Proc; 2007 May; 82(5):543-50. PubMed ID: 17493418
[TBL] [Abstract][Full Text] [Related]
40. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW
Eur J Prev Cardiol; 2013 Dec; 20(6):1080-7. PubMed ID: 23644489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
